 |
인쇄하기
취소
|
Chong Kun Dang pins hopes on new antidiabetic agent
With local pharmaceutical companies competing within and beyond national borders, Chong Kun Dang Pharmaceuticals may find that its latest breakthrough will give it a leg up in the market.
The Korea Food and Drug Administration earlier this month okayed Phase 3 clinical trial of the company's new antidiabetic medicine, called CKD-501.
Its key ingredient is lobeglitazone sulfate, and its ...
The Korea Food and Drug Administration earlier this month okayed Phase 3 clinical trial of the company's new antidiabetic medicine, called CKD-501.
Its key ingredient is lobeglitazone sulfate, and its ...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.